ArticleMolecular and clinical oncology2026
Benefits and risks of prophylactic glucocorticoids in platinum chemotherapy for extensive-stage small-cell lung cancer: A retrospective study.
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the present study was to analyze the effects of prophylactic glucocorticoid use on the efficacy and adverse reactions of platinum-based intravenous regimens in patients with extensive-stage small-cell lung cancer (ES-SCLC). The present study retrospectively analyzed 103 newly diagnosed patients with ES-SCLC treated with etoposide plus platinum at the First Affiliated Hospital of Anhui Medical University from August 2022 to December 2024. Patients were divided into glucocorticoid (63 cases) and control (40 cases) groups. Baseline characteristics, adverse reaction rates and treatment outcomes were compared between groups. The hormone group showed no significant differences in objective response rate (ORR) and disease control rate (DCR) but had lower incidences of nausea/vomiting (P=0.005), constipation (P=0.002) and leukopenia (P=0.009). In patients also receiving immune checkpoint inhibitors (ICIs), the hormone group had improved renal function protection (P=0.026). Although hypertension incidence was higher in the hormone group, the difference was not statistically significant (P>0.05). Hyperglycemia rates and median survival time were similar between groups. In conclusion, prophylactic glucocorticoids do not significantly affect ORR, DCR, or median survival in patients with ES-SCLC on etoposide plus platinum with or without ICIs but can reduce nausea/vomiting, constipation and leukopenia. They may protect kidney function when combined with ICIs. No major adverse events were linked to glucocorticoid use, so their prophylactic use is recommended in platinum-based ES-SCLC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.